Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 6
1949 2
1951 4
1952 4
1953 1
1954 5
1955 3
1956 4
1957 3
1958 5
1959 4
1960 9
1961 11
1962 10
1963 11
1964 8
1965 6
1966 1
1967 4
1968 3
1969 5
1970 4
1971 7
1972 9
1973 8
1974 11
1975 10
1976 7
1977 8
1978 12
1979 20
1980 14
1981 21
1982 23
1983 25
1984 25
1985 36
1986 36
1987 56
1988 50
1989 68
1990 55
1991 59
1992 91
1993 87
1994 70
1995 78
1996 69
1997 60
1998 93
1999 70
2000 97
2001 73
2002 96
2003 83
2004 115
2005 118
2006 170
2007 154
2008 156
2009 130
2010 169
2011 156
2012 188
2013 176
2014 221
2015 201
2016 226
2017 228
2018 279
2019 242
2020 320
2021 389
2022 356
2023 380
2024 157

Text availability

Article attribute

Article type

Publication date

Search Results

5,562 results

Results by year

Filters applied: . Clear all
Page 1
Graves' ophthalmopathy.
Bahn RS. Bahn RS. N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750. N Engl J Med. 2010. PMID: 20181974 Free PMC article. Review.
Graves' ophthalmopathy, also called Graves' orbitopathy, is a potentially sight-threatening ocular disease that has puzzled physicians and scientists for nearly two centuries.(-) Generally occurring in patients with hyperthyroidism or a history of hyperthyroi …
Graves' ophthalmopathy, also called Graves' orbitopathy, is a potentially sight-threatening ocular disease that has puz …
Treatment of Graves' ophthalmopathy.
González-García A, Sales-Sanz M. González-García A, et al. Med Clin (Barc). 2021 Feb 26;156(4):180-186. doi: 10.1016/j.medcli.2020.07.031. Epub 2020 Oct 14. Med Clin (Barc). 2021. PMID: 33069387 Review. English, Spanish.
Graves' ophthalmopathy is an inflammatory disease with primary involvement of the extraocular muscles and the orbit. ...In recent years, therapeutic novelties have been described in terms of the dosage of the immunosuppressive treatments used, as well as the emergen …
Graves' ophthalmopathy is an inflammatory disease with primary involvement of the extraocular muscles and the orbit. ...In rec …
2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.
Hoang TD, Stocker DJ, Chou EL, Burch HB. Hoang TD, et al. Endocrinol Metab Clin North Am. 2022 Jun;51(2):287-304. doi: 10.1016/j.ecl.2021.12.004. Epub 2022 May 11. Endocrinol Metab Clin North Am. 2022. PMID: 35662442 Free PMC article. Review.
The management of hyperthyroidism and extrathyroidal manifestations of Graves disease remains complex. Considerations that include patient preference, age, comorbidity, pregnancy, tobacco smoking, and social determinants of health must all be weaved into a cohesive managem …
The management of hyperthyroidism and extrathyroidal manifestations of Graves disease remains complex. Considerations that include pa …
The risk factors for Graves' ophthalmopathy.
Cao J, Su Y, Chen Z, Ma C, Xiong W. Cao J, et al. Graefes Arch Clin Exp Ophthalmol. 2022 Apr;260(4):1043-1054. doi: 10.1007/s00417-021-05456-x. Epub 2021 Nov 17. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 34787691 Review.
PURPOSE: This review aimed to provide an overview of current research into the risk factors for Graves' ophthalmopathy (GO). METHODS: To find information about the risk factors for GO, the research database PubMed was searched and relevant articles were obtained to …
PURPOSE: This review aimed to provide an overview of current research into the risk factors for Graves' ophthalmopathy (GO). M …
Euthyroid Graves' ophthalmopathy.
Schattner A, Voichanski S, Pollack R, Uliel L. Schattner A, et al. QJM. 2023 Nov 24;116(11):942-943. doi: 10.1093/qjmed/hcad176. QJM. 2023. PMID: 37471697 No abstract available.
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy.
Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Gonnella D, Giusti C, Virili C, Centanni M, Shoenfeld Y, Ferrari SM. Antonelli A, et al. Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101388. doi: 10.1016/j.beem.2020.101388. Epub 2020 Feb 4. Best Pract Res Clin Endocrinol Metab. 2020. PMID: 32059832 Review.
Graves' disease (GD) is characterized by thyrotoxicosis, caused by the presence of circulating thyroid stimulating antibodies (TSAb), that are determinant also in the pathogenesis of its extrathyroidal manifestations [Graves' ophthalmopathy (GO), pretibial my …
Graves' disease (GD) is characterized by thyrotoxicosis, caused by the presence of circulating thyroid stimulating antibodies (TSAb), …
Treatment of Graves' ophthalmopathy.
Alijotas-Reig J. Alijotas-Reig J. Med Clin (Barc). 2022 Jan 21;158(2):93. doi: 10.1016/j.medcli.2021.03.011. Epub 2021 Jun 16. Med Clin (Barc). 2022. PMID: 34144800 English, Spanish. No abstract available.
Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy.
Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Bartalena L, et al. Front Endocrinol (Lausanne). 2020 Nov 30;11:615993. doi: 10.3389/fendo.2020.615993. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33329408 Free PMC article. Review.
GO is the most frequent extrathyroidal manifestation of Graves' disease, although it may rarely occur in euthyroid/hypothyroid patients with chronic autoimmune thyroiditis. ...The prevalence of GO is lower than in the past among patients with recent onset Graves' hy …
GO is the most frequent extrathyroidal manifestation of Graves' disease, although it may rarely occur in euthyroid/hypothyroid patien …
Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy.
Kotwal A, Stan M. Kotwal A, et al. Horm Metab Res. 2018 Dec;50(12):871-886. doi: 10.1055/a-0739-8134. Epub 2018 Oct 4. Horm Metab Res. 2018. PMID: 30286486 Review.
The course and pathogenesis of Graves' disease and Graves' ophthalmopathy are interdependent, influencing each other's therapeutic choices. ...Some of them (tocilizumab and teprotumumab) are very promising but further evaluation is needed before we can establ …
The course and pathogenesis of Graves' disease and Graves' ophthalmopathy are interdependent, influencing each other's …
Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.
Li X, Li S, Fan W, Rokohl AC, Ju S, Ju X, Guo Y, Heindl LM. Li X, et al. Int Ophthalmol. 2023 Apr;43(4):1437-1449. doi: 10.1007/s10792-022-02537-6. Epub 2022 Oct 22. Int Ophthalmol. 2023. PMID: 36272013 Free PMC article. Review.
Graves ophthalmopathy (GO), which occurs in autoimmune thyroid disease, can reduce patients' quality of life due to its impact on visual function, physical appearance, and emotional health. ...
Graves ophthalmopathy (GO), which occurs in autoimmune thyroid disease, can reduce patients' quality of life due to its impact …
5,562 results

Searches related to "graves ophthalmopathy"